Literature DB >> 27194547

Tularemia vaccines.

Daniela Putzova1, Iva Senitkova1, Jiri Stulik2.   

Abstract

Francisella tularensis is the causative agent of the potentially lethal disease tularemia. Due to a low infectious dose and ease of airborne transmission, Francisella is classified as a category A biological agent. Despite the possible risk to public health, there is no safe and fully licensed vaccine. A potential vaccine candidate, an attenuated live vaccine strain, does not fulfil the criteria for general use. In this review, we will summarize existing and new candidates for live attenuated and subunit vaccines.

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27194547     DOI： 10.1007/s12223-016-0461-z

Source DB:  PubMed          Journal:  Folia Microbiol (Praha)        ISSN： 0015-5632            Impact factor:   2.099


  89 in total

1.  Transcriptional profiling of the peripheral blood response during tularemia.

Authors:  H Andersson; B Hartmanová; E Bäck; H Eliasson; M Landfors; L Näslund; P Rydén; A Sjöstedt
Journal:  Genes Immun       Date:  2006-07-06       Impact factor: 2.676

2.  Genetic modification of the O-polysaccharide of Francisella tularensis results in an avirulent live attenuated vaccine.

Authors:  Tae-Hyun Kim; Jessica T Pinkham; Sara J Heninger; Sabina Chalabaev; Dennis L Kasper
Journal:  J Infect Dis       Date:  2011-10-03       Impact factor: 5.226

Review 3.  Tularaemia.

Authors:  A Tärnvik; L Berglund
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

4.  Characterization of the O antigen gene cluster and structural analysis of the O antigen of Francisella tularensis subsp. tularensis.

Authors:  Joann L Prior; Richard G Prior; Paul G Hitchen; Helen Diaper; Kate F Griffin; Howard R Morris; Anne Dell; Richard W Titball
Journal:  J Med Microbiol       Date:  2003-10       Impact factor: 2.472

5.  An improved vaccine for prevention of respiratory tularemia caused by Francisella tularensis SchuS4 strain.

Authors:  Chandra Shekhar Bakshi; Meenakshi Malik; Manish Mahawar; Girish S Kirimanjeswara; Karsten R O Hazlett; Lance E Palmer; Martha B Furie; Rajendra Singh; J Andres Melendez; Timothy J Sellati; Dennis W Metzger
Journal:  Vaccine       Date:  2008-08-08       Impact factor: 3.641

Review 6.  Francisella tularensis: unravelling the secrets of an intracellular pathogen.

Authors:  Petra C F Oyston
Journal:  J Med Microbiol       Date:  2008-08       Impact factor: 2.472

7.  Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection.

Authors:  M Ericsson; G Sandström; A Sjöstedt; A Tärnvik
Journal:  J Infect Dis       Date:  1994-07       Impact factor: 5.226

8.  Protection afforded against aerosol challenge by systemic immunisation with inactivated Francisella tularensis live vaccine strain (LVS).

Authors:  J E Eyles; M G Hartley; T R Laws; P C F Oyston; K F Griffin; R W Titball
Journal:  Microb Pathog       Date:  2007-08-21       Impact factor: 3.738

9.  Characterization and sequencing of a respiratory burst-inhibiting acid phosphatase from Francisella tularensis.

Authors:  T J Reilly; G S Baron; F E Nano; M S Kuhlenschmidt
Journal:  J Biol Chem       Date:  1996-05-03       Impact factor: 5.157

10.  Low dose vaccination with attenuated Francisella tularensis strain SchuS4 mutants protects against tularemia independent of the route of vaccination.

Authors:  Dedeke Rockx-Brouwer; Audrey Chong; Tara D Wehrly; Robert Child; Deborah D Crane; Jean Celli; Catharine M Bosio
Journal:  PLoS One       Date:  2012-05-25       Impact factor: 3.240
View more
  5 in total

1.  Immunoproteomic Analysis of Antibody Response of Rabbit Host Against Heat-Killed Francisella tularensis Live Vaccine Strain.

Authors:  Ritu Gaur; Syed Imteyaz Alam; Dev Vrat Kamboj
Journal:  Curr Microbiol       Date:  2017-02-23       Impact factor: 2.188

Review 2.  Innate Immune Recognition: Implications for the Interaction of Francisella tularensis with the Host Immune System.

Authors:  Zuzana Krocova; Ales Macela; Klara Kubelkova
Journal:  Front Cell Infect Microbiol       Date:  2017-10-16       Impact factor: 5.293

3.  Intranasal administration of a two-dose adjuvanted multi-antigen TMV-subunit conjugate vaccine fully protects mice against Francisella tularensis LVS challenge.

Authors:  Alison A McCormick; Aisha Shakeel; Chris Yi; Hardeep Kaur; Ahd M Mansour; Chandra Shekhar Bakshi
Journal:  PLoS One       Date:  2018-04-23       Impact factor: 3.240

4.  A case of ulceroglandular tularemia presenting with lymphadenopathy and an ulcer on a linear morphoea lesion surrounded by erysipelas.

Authors:  Alessandra Balestra; Hekuran Bytyci; Caroline Guillod; Antonio Braghetti; Luigia Elzi
Journal:  Int Med Case Rep J       Date:  2018-11-12

5.  Deletion Mutants of Francisella Phagosomal Transporters FptA and FptF Are Highly Attenuated for Virulence and Are Protective Against Lethal Intranasal Francisella LVS Challenge in a Murine Model of Respiratory Tularemia.

Authors:  Brandi E Hobbs; Courtney A Matson; Vasileios I Theofilou; Tonya J Webb; Rania H Younis; Eileen M Barry
Journal:  Pathogens       Date:  2021-06-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.